Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) 580299 Vaccine in Healthy Chinese Female Subjects

GlaxoSmithKline1 site in 1 country750 target enrollmentOctober 24, 2009

ConditionsInfections, Papillomavirus

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Infections, Papillomavirus
Sponsor: GlaxoSmithKline
Enrollment: 750
Locations: 1
Primary Endpoint: Geometric Mean Titers (GMTs) for Antibodies Against Human Papillomavirus (HPV)-16/18 Antigens
Status: Completed
Last Updated: 7 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This study is designed to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals' human papillomavirus (HPV) vaccine in pre-teen and adolescent female subjects aged 9 - 17 years. One group of subjects will receive the HPV vaccine and the other group will receive the control.

Registry

clinicaltrials.gov

Start Date

October 24, 2009

End Date

December 8, 2010

Last Updated

7 years ago

Study Type

Interventional

Study Design

Parallel

Sex

Female

Investigators

Sponsor

GlaxoSmithKline

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Subjects who the investigator believes that they or their parent(s)/Legally Acceptable Representative(s) (LAR) can and will comply with the requirements of the protocol.
•Healthy Chinese females between and including 9 and 17 years of age at the time of the first vaccination.
•Written informed consent obtained from the parent(s)/LAR(s) of the subject and informed assent obtained from the subject, if appropriate, prior to enrolment.
•Healthy subjects as established by medical history and history-directed clinical examination before entering into the study.
•Subjects must not be pregnant. Absence of pregnancy will be verified with a urine pregnancy test before each vaccination.
•Subjects must be either of non-childbearing potential, or if of childbearing potential, they must be abstinent or have practiced adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and agree to continue such precautions for 2 months after completion of the vaccination series.

Exclusion Criteria

•Use of any investigational or non-registered product other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.
•Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.
•Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days before and 30 days after (i.e., Days 0-29) the first dose of vaccine.
•Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
•A subject planning to become pregnant, likely to become pregnant or planning to discontinue contraceptive precautions during the study period and up to two months after the last vaccine dose.
•Pregnant or breastfeeding. Subjects must be at least three months post-pregnancy and not breastfeeding to enter the study.
•Previous vaccination against HPV or planned administration of any HPV vaccine other than that foreseen by the protocol during the study period.
•Previous administration of components of the study vaccine.
•History of chronic condition(s) requiring treatment such as cancer or autoimmune disease.
•History of allergic disease, suspected allergy or reactions likely to be exacerbated by any component of the vaccine.

Outcomes

Primary Outcomes

Geometric Mean Titers (GMTs) for Antibodies Against Human Papillomavirus (HPV)-16/18 Antigens

Time Frame: One month after the third dose (at Month 7)

Titers were given as geometric mean titers and were measured by Enzyme-linked Immunosorbent Assay (ELISA) and expressed as Enzyme-linked Immunosorbent Assay Units Per Milliliter (EL.U/mL).

Secondary Outcomes

Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms(During the 7 days (Days 0 - 6) following each vaccination)
Number of Subjects Seroconverted for Anti-HPV-16 and Anti-HPV-18 Antibodies(At Month 7)
Number of Subjects Reporting Pregnancies and Pregnancy Outcomes(Throughout the study period (from Day 0 up to Month 12))
Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms(During the 7 days (Days 0 - 6) following each vaccination)
Number of Subjects Reporting Medically Significant Conditions (MSCs)(Throughout the study period (from Day 0 up to Month 12))
Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs)(Throughout the study period (from Day 0 up to Month 12))
Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs)(Within 30 days (Days 0 - 29) after any vaccination)